Safety of leukoreduced, cytomegalovirus (CMV)-untested components in CMV-negative allogeneic human progenitor cell transplant recipients

被引：27
|
作者：
Nash, Tammon [1 ]
Hoffmann, Sandra [2 ]
Butch, Suzanne [2 ]
Davenport, Robertson [2 ]
Cooling, Laura [2 ]
机构：
[1] Michigan Blood, Grand Rapids, MI USA
[2] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA
来源：
TRANSFUSION | 2012年 / 52卷 / 10期
关键词：
BLOOD-PRODUCTS; TRANSFUSION; TRANSMISSION; INFECTION;
D O I：
10.1111/j.1537-2995.2012.03739.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2270 / 2272
页数：3
相关论文
共 50 条
  • [41] Breakthrough CMV Infections on Letermovir Prophylaxis in CMV-Seropositive Allogeneic Hematopoeitic Cell Transplant (allo-HCT) Recipients
    Shigle, Terri Lynn
    Handy, Victoria Wehr
    Foolad, Farnaz
    Khawaja, Fareed
    Aitken, Samuel L.
    Chemaly, Roy F.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [42] The Association between Cytomegalovirus Immune Globulin (CMVIG) and Recipient and Graft Survival in CMV Donor Positive/CMV Recipient Negative Renal Transplant Recipients
    Snydman, David R.
    Ulsh, Paula
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 326 - 326
  • [43] Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection
    Chiereghin, Angela
    Potena, Luciano
    Borgese, Laura
    Gibertoni, Dino
    Squarzoni, Diego
    Turello, Gabriele
    Petrisli, Evangelia
    Piccirilli, Giulia
    Gabrielli, Liliana
    Grigioni, Francesco
    Lazzarotto, Tiziana
    JOURNAL OF CLINICAL MICROBIOLOGY, 2018, 56 (04)
  • [44] EXPERIENCE WITH THE USE OF MARIBAVIR IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH REFRACTORY OR RESISTANT CYTOMEGALOVIRUS (CMV)
    Fernandez Perez, Monica
    Ceballos Bolanos, Candela
    Oiartzabal Ormategui, Itziar
    Arratibel Zalacain, Nerea
    Millacoy Austenrritt, Pamela
    Aranguren Ostolaza, Marina
    Viguria Alegria, Maria Cruz
    Panizo Santos, Carlos Manuel
    BONE MARROW TRANSPLANTATION, 2024, 59 : 475 - 476
  • [45] Relationship between HLA alleles and Cytomegalovirus (CMV) infection in hematopoietic stem cell transplant recipients
    Chen, Y
    Rocha, V
    Bittencourt, H
    Scieux, C
    Loiseau, P
    Chevret, S
    Charron, D
    Esperou, H
    Devergie, A
    Guardiola, P
    Socie, G
    Gluckman, E
    Ribaud, P
    BONE MARROW TRANSPLANTATION, 2001, 27 : S52 - S52
  • [46] Clinical Utility of Cytomegalovirus Cell Mediated Immunity in Transplant Recipients with Low Level CMV Viremia
    Lisboa, L. F.
    Humar, A.
    Silva, M., Jr.
    Huang, J.
    Wilson, L. E.
    Kumar, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 115 - 115
  • [47] Safety and Effectiveness of Low-Dose Cytomegalovirus Valganciclovir Prophylaxis in CMV Seropositive Lung Transplant Recipients
    Lehikoinen, R. A.
    Syrjala, S.
    Heliovaara, E.
    Tikkanen, J.
    Lemstrom, K.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (04): : S486 - S486
  • [48] A Single Center Experience of Letermovir for the Prevention of CMV Infection in CMV-Seropositive Allogeneic Cell Transplant (Allo-HCT) Recipients
    Foolad, Farnaz
    Shigle, Terri Lynn
    Handy, Victoria Wehr
    Khawaja, Fareed
    Aitken, Samuel L.
    Chemaly, Roy F.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [49] Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients
    Seo, Euri
    Choi, Eun Seok
    Kim, Jung Hwa
    Kim, Hyery
    Koh, Kyung-Nam
    Im, Ho Joon
    Lee, Jina
    PLOS ONE, 2021, 16 (02):
  • [50] CMV REACTIVATION AFTER STOPPING LETERMOVIR PRIMARY PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS
    Chavaz, Lara
    Royston, Lena
    Masouridi-Levrat, Stavroula
    Mamez, Anne-Claire
    Giannotti, Federica
    Morin, Sarah
    Van Delden, Christian
    Chalandon, Yves
    Neofytos, Dionysios
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 93 - 93
12345